Scientific publications
Publications produced in collaboration CNRS/MEDESIS:
Couly S1, Paucard A1, Bonneaud N1, Maurice T1, Benigno L2, Jourdan C1, Cohen-Solal C3, Vignes M3, Maschat F ; Improvement of BDNF signaling by P42 peptide in Huntington’s disease – Hum Mol Genet. (2018)
Here is a list of publications in which Medesis Pharma staff members are co-authors, or which mention the Aonys® delivery plateform of Medesis Pharma.
Wilson EN, Do Carmo S, Welikovitch LA, Hall H, Aguilar LF, Foret MK, Iulita F, Jia DT, Marks AR, Allard S, Emmerson JT, Ducatenzeiler A, and Cuello C
Wilson EN, Do Carmo S, Iulita MF, Hall H, Austin G, Jia D, Malcolm J, Foret M, Marks AR, Butterfield D and Cuello C
Aroa Relaño-Ginés, Sylvain Lehmann, Elsa Brillaud, Maxime Belondrade, Danielle Casanova, Claire Hamela, Charles Vincent, Sophie Poupeau, Jerome Sarniguet, Maria-Teresa Alvarez-Martinez, Damien Arnaud, Jean-Claude Maurel, and Carole Crozet
Lithium as a disease-modifying agent for prion disease, Translational Psychiatry (2018)
Couly S1, Paucard A1, Bonneaud N1, Maurice T1, Benigno L2, Jourdan C1, Cohen-Solal C3, Vignes M3, Maschat F
Improvement of BDNF signalling by P42 peptide in Huntington’s disease – Hum Mol Genet. (2018)
Translational Psychiatry (2017) 7, e1190. See the article here
The P42 peptide and Peptide-based therapies for Huntington’s disease.
Orphanet Journal of Rare Diseases (2016) 11:24. See the article here
J Colloid Interface Sci. 2015 Nov 1;457:152-61.
Phase behavior of reverse microemulsions based on Peceol(®).
PLoS One. 2014 Feb 14;9(2):e88797. See the article here
Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease.
Acta Neuropathol Commun. 2014 Aug 5;2:86. See the article here
NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.
Neurobiol Dis. 2012 Dec;48(3):282-9.
Julien Champagne, Laetitia K. Linares, Benjamin Maurel, Alexandre Zampieri, Maeva Moreno, Ivanna Fuentes, Emeric Dubois, Dany Severac, Adrien Decorsière, Frédéric Bienvenu.
TAG-RNAi overcomes off-target effects in cancer models.
Springer Nature , Published 26 september 2019.